摘要
目的:研究布地奈德福莫特罗联合孟鲁司特钠治疗儿童咳嗽变异性哮喘(CVA)的疗效及对肺功能的影响。方法:选取2017年1月~2018年5月在本院接受治疗的100例CVA患儿作为研究对象,按照随机数字表法分为对照组和研究组,各50例。对照组予以布地奈德福莫特罗治疗;研究组在对照组基础上予以孟鲁司特钠治疗。观察两组治疗前和治疗后肺功能指标[第1秒用力呼气容积(FEV1)、第1秒用力呼气容积/用力肺活量(FEV1/FVC)、最大呼气流量占预计值的百分比(PEF%pred)]、咳嗽症状评分、血清相关指标[肿瘤坏死因子-α(TNF-α)、免疫球蛋白E(Ig E)水平以及嗜酸性粒细胞(EOS)计数]变化情况,以及临床疗效和不良反应情况。结果:治疗后,两组FEV1、FEV1/FVC、PEF%pred高于治疗前,且研究组高于对照组(P <0.05)。治疗后,两组日间咳嗽评分、夜间咳嗽评分、TNF-α、Ig E水平以及EOS计数低于治疗前,且研究组低于对照组(P <0.05)。研究组总有效率(82.00%)高于对照组(62.00%,P <0.05)。两组不良反应总发生率无统计学差异(P> 0.05)。结论:布地奈德福莫特罗联合孟鲁司特钠治疗儿童CVA的疗效确切,安全性较好,值得推广应用。
Objective: To study the efficacy of budesonide and formoterol fumarate with montelukast sodium in children with cough variant asthma( CVA) and its effect on lung function. Methods: 100 children with CVA admitted for treatment in our hospital from January 2017 to May 2018 were selected as the research subjects,and divided into the control group and the experimental group by the random number table,50 cases in each group. The control group was given budesonide and formoterol fumarate. The experimental group was treated with a combination of montelukast sodium on the basis of the control group. Lung function indexes [forced expiratory volume in 1 s( FEV1),forced expiratory volume in 1 s/forced vital capacity( FEV1/FVC),the percentage of maximum expiratory flow in the predicted value( PEF% pred) ],cough symptom score,the levels of serum related indexes [tumor necrosis factor-α( TNF-α),immunoglobulin E( IgE) and eosinophil( EOS) count],clinical efficacy and adverse reactions were observed before and after treatment in the two groups. Results: After treatment,FEV1,FEV1/FVC and PEF% pred in both groups were higher than before treatment,and those in the experimental group were higher than in the control group( P < 0. 05). After treatment,daytime cough score,night cough score,the level of TNF-αand Ig E,EOS count in both groups were lower than before treatment,and those in the experimental group were lower than in the control group( P < 0. 05). The total effective rate of the study group( 82. 00%) was higher than that of the control group( 62. 00%,P < 0. 05). There was no significant difference in the total incidence of adverse reactions between the two groups( P > 0. 05). Conclusion: Budesonide and formoterol fumarate with montelukast sodium in the treatment of CVA have a definite efficacy and good safety,which is worthy popularizing and applying.
作者
柳清梅
LIU Qing-mei(Department of Clinical Laboratory,Luoyang Maternal and Child Health Hospital,Luoyang 471023,China)
出处
《中国合理用药探索》
2021年第6期67-71,共5页
Chinese Journal of Rational Drug Use
关键词
咳嗽变异性哮喘
孟鲁司特钠
布地奈德福莫特罗
疗效
肺功能
cough variant asthma
montelukast sodium
budesonide and formoterol fumarate
efficacy
lung function
